Testosterone replacement therapy: Current trends and future directions

Human Reproduction Update

Volumn 10, Issue 5, 2004, Pages 409-419

  Nieschlag, E ^a   Behre, H M ^b   Bouchard, P ^c   Corrales, J J ^d   Jones, T H ^e   Stalla, G K ^f   Webb, S M ^g   Wu, F C W ^h  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Lab de Thrombose Experimentale   (France)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^f MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^g HOSPITAL SANT PAU   (Spain)

^h MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Male hypogonadism; Testosterone replacement

Indexed keywords

ANDROSTANOLONE; ANDROTOP; FLUOXYMESTERONE; LIPID; LONG ACTING DRUG; MESTEROLONE; METHYLTESTOSTERONE; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

AGING; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PELLET; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HEALTH CARE DELIVERY; HEMATOCRIT; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LIPID BLOOD LEVEL; LIVER TOXICITY; LUNG EMBOLISM; MALE; MALE SEXUAL DYSFUNCTION; MOOD DISORDER; MUSCLE ATROPHY; MUSCLE WEAKNESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE; REVIEW; RISK BENEFIT ANALYSIS; SKIN ALLERGY; SKIN IRRITATION; SLEEP APNEA SYNDROME; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH;

ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 4544264671     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmh035     Document Type: Review

References (96)

1. Abramsky L and Chapple J (1997) 47,XXY (Klinefelter's syndrome) and 47,XYY: estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. Prenat Diagn 17,363-368.
2. American Association of Clinical Endocrinologists (AACE). Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Available at: http://www.aace.com/clin/guidelines/hypogonadism.pdf
3. Atkinson LE, Chang Y-L and Snyder PJ (1998) Long-term experience with testosterone replacement through scrotal skin. In Nieschlag E and Behre HM (eds) Testosterone. Action, Deficiency, Substitution. Springer, Berlin, Germany, pp 365-388.
4. Bagatell CJ and Bremner WJ (1996) Androgens in men -uses and abuses. N. Engl J Med 334,707-714.
5. Baisley KJ, Boyce MJ, Bukofzer S, Pradhan R and Warrington SJ (2002) Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin. J Endocrinol 175,813-819.
6. Behre HM and Nieschlag E (1992) Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75, 1204-1210.
7. Behre HM, Bohmeyer J and Nieschlag E (1994) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 40,341-349.
8. Behre HM, Kliesch S, Leifke E, Link TM and Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82,2386-2390.
9. Behre HM, von Eckardstein S, Kliesch S and Nieschlag E (1999) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over seven to ten years. Clin Endocrinol 50,629-635.
10. Behre HM, Yeung CH, Holstein AE, Weinbauer GF, Gassner P and Nieschlag E (2000) Diagnosis of Male Infertility and Hypogonadism. In Nieschlag E and Behre HM (eds) Andrology: Male reproductive health and dysfunction. Springer, Heidelberg, pp 90-124.
11. Behre HM, Wang C, Handelsman DJ and Nieschlag E (2004) Pharmacology of testosterone preparations. In Nieschlag E and Behre HM (eds) Testosterone. Action, Deficiency, Substitution. 3rd edn. Cambridge University Press,pp 405-444.
12. Benito M, Gomberg B, Wehrli FW, Weening RH, Zemel B, Wright AC, Song HK, Cucchiara A and Snyder PJ (2003) Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 88, 1497-1502.
13. Bhasin S., Woodhouse L, Casaburi R et al. (2001) Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281,E1172-E1181.
14. Bojesen A, Juul S and Gravholt CH (2003) Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 88,622-626.
15. Conway AJ, Handelsman DJ, Lording DW, Stuckey B and Zajac JD, on behalf of the Endocrine Society of Australia, (2000) Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Austr 172,220-224.
16. Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157,439-444.
17. De Lorimier AA, Gordon GS, Lower RC and Carbone JV (1965) Methyl-testosterone, related steroids, and liver function. Arch Int Med 116, 289-294.
18. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP and Fraser WD (2003) Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol 58,710-717.
19. Dobs AS, Hoover DR, Chen MC and Allen R (1998) Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 83,33-39.
20. Dobs AS, Kipnes MS, Matsumoto AM and Wang C (2004) Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 20, 729-738.
21. Endocrine Society press release. 'Endocrine Society highlights importance of appropriate diagnosis and treatment of low testosterone' (2001) Available at: http://www.endo-society.org/pubrelations/pressReleases/archives/ 2001/low.cfm
22. English KM, Steeds RP, Jones TH, Diver MJ and Channer KS (2000) Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation 102,1906-1911.
23. English KM, Jones RD, Jones TH, Morice AH and Channer KS (2002) Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 25,455-458.
24. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R and Khosla S (2002) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106,1553-1560.
25. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ and McKinlay JB (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87,589-598.
26. Felsenberg D, Silman AJ, Lunt M, Armbrecht G, Ismail AA, Finn JD, Cockerill WC, Banzer D, Benevolenskaya LI and Bhalla A (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17,716-724.
27. Francis RM (2001) Androgen replacement in aging men. Calcif Tissue Int 69,235-238.
28. Gennari L, Merlotti D, Martini G, Gonnelli S, Cranci B, Campagna S, Lucani B, Dal Canto N, Valenti R, Gennari C and Nuti R (2003) Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 88,5327-5333.
29. Hajjar RR, Kaiser FE and Morley JE (1997) Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82,3793-3796.
30. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A and Pols HA (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87,3632-3639.
31. Handelsman DJ, Conway AJ and Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71,216-222.
32. Handelsman DJ, Mackey MA, Howe C, Turner L and Conway AJ (1997) An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol 47,311-316.
33. Harman SM, Metter EJ, Tobin JD, Pearson J and Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86,724-731.
34. Institute of Medicine (2004). Testosterone and aging: clinical research directions. The National Academies Press, Washington. Available at: http://www.nap.edu/openbook/0309090636/html/
35. Jones RD, Pugh PJ, Jones TH and Channer KS (2003a) The vaso-dilatory action of testosterone - a potassium-channel opening or a calcium channel antagonistic action. Brit J Pharm 138,733-744.
36. Jones RD, Pugh PJ, Hall J, Channer KS and Jones TH (2003b) Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocr 148,111-120.
37. 2a-mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: Evidence of an antagonistic action upon store operated calcium channels. J Endocrinol 178,381-393.
38. Jordan WP Jr (1997) Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. Am J Contact Dermat 8,108-113.
39. Kaufman JM and Vermeulen A (1997) Declining gonadal function in elderly men. Ballières Clin Endocrinol Metab 11,289-309.
40. Kenny AM, Prestwood KM, Gruman CA, Marcello KM and Raisz LG (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci 56A,M273.
41. Korbonits M, Slawik M, Cullen D, Ross RJ, Stalla G, Schneider H, Reincke M, Bouloux PM and Grossman AB (2004) A comparison of a novel testosterone bioadhesive buccal tablet, Striant™, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 89, 2039-2043.
42. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R and Finkelstein JS (2003) Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88,204-210.
43. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L and Lavie P (2002) Decreased pituitary-gonadal secretion in men with obstructive sleep apnoea. J Clin Endocrinol Metab 87,3394-3398.
44. Mackey MA, Conway AJ and Handelsman DJ (1995) Tolerability of intramuscular injections in testosterone ester in oil vehicle. Hum Reprod 10, 862-865.
45. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH and Channer KS (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and mood. Heart 90,871-876.
46. Matsumoto AM (2002) Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol Med Sci 57A,M76-M99.
47. Matsumoto AM and Bremner WJ (2004) Editorial: Serum testosterone assay - accuracy matters. J Clin Endocrinol Metab 89,520-524.
48. Melton LJ, III (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14 (Suppl 1),S1-S8.
49. Mittan D, Lee S, Miller E, Perez RC, Basler JW and Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87,3656-3661.
50. Morales A and Lunenfeld B (2002) Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 5,74-86.
51. Morales A, Johnston B, Heaton JP and Lundie M (1997) Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157,849-854.
52. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D and Perry HM, III (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49,1239-1242.
53. Morley JE, Ping P and Perry HM, III (2002) Evaluation of assays available to measure free testosterone. Metabolism 51,554-559.
54. Nadell J and Kosek J (1977) Peliosis hepatis: Twelve cases associated with oral androgen therapy. Arch Pathol Lab Med 101,405-410.
55. Nieschlag E (1998) If testosterone, which testosterone? Which androgen regimen should be used for supplementation in older men? Formulation, dosing, and monitoring issues. J Clin Endocrinol Metab 83,3443-3445.
56. Nieschlag E (2000) Classification of andrological disorders. In Nieschlag E and Behre HM (eds) Andrology: Male reproductive health and dysfunction. 2nd edn. Springer, Berlin, pp 83-88.
57. Nieschlag E and Behre HM (2004) Clinical uses of testosterone in hypogonadism and other conditions. In Nieschlag E and Behre HM (eds) Testosterone. Action, Deficiency, Substitution. 3rd edn. Cambridge University Press, pp 375-403.
58. Nieschlag E, Lammers U, Freischem CW, Langer K and Wickings EJ (1982) Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 55,676-681.
59. Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A and Gundogan MA (1996) Effects of gonadotropin and testosterone treatments on Lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 81, 3372-3378.
60. Parker S and Armitage M (1999) Experience with transdermal testosterone replacement therapy for hypogonadal men. 50,57-62.
61. Pugh PJ, Jones TH and Channer KS (2003) Acute haemodynamic effects of testosterone in men with chronic heart failure. European Heart Journal 24,909-915.
62. Pugh PJ, Jones RD, West JN, Jones TH and Channer KS (2004) Testosterone improves functional capacity and symptoms in men with heart failure. Heart 90,446-447.
63. Rolf C, Knie U, Lemmnitz G and Nieschlag E (2002) Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol 56,637-641.
64. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M and Chierchia SL (1999) Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99,1666-1670.
65. Rosner W (2001) Letter to the editor: An extraordinary inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 86,2903.
66. Ross RJ, Jabbar A, Jones TH, Roberts B, Dunkley K, Hall J, Long A, Levine H and Cullen DR (2004) Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur J Endocrinol 150,57-63.
67. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F and Schalken J (1999) Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 20,22-45.
68. Sandblom RE, Matsumoto AM, Schoene RB, Lee KA, Giblin EC, Bremner WJ and Pierson DJ (1983) Obstructive sleep apnoea induced by testosterone administration. N Engl J Med 308,508-510.
69. 2+ channels. Biochem Biophys Res Common 318,503-506.
70. Seeman E (2001) Clinical review 137: Sexual dimorphism in skeletal size, density and strength. J Clin Endocrinol Metab 86,4576-4584.
71. Shaneyfelt T, Husein R, Bubley G and Mantzoros CS (2000) Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18,847-853.
72. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L and Eschwege E (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 82,682-685.
73. Simoni M (2004) Methodology for measuring testosterone, DHT and SHBG in a clinical seting. In Nieschlag E and Behre HM (eds), Testosterone: Action, Deficiency, Substitution. Cambridge University Press, Cambridge, pp 641-664.
74. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF and Davies JS (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86,4261-4267.
75. Snyder PJ, Peachey H, Hannoush P et al. (1999a) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84,1966-1972.
76. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ and Strom BL (1999b) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84,2647-2653.
77. Snyder PJ, Peachey H, Berlin JA et al. (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85, 2670-2677.
78. Sorva R, Kuusi T, Taskinen MR, Perheentupa J and Nikkila EA (1988) Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 69,191-197.
79. Spelsberg TC, Subramaniam M, Riggs BL and Khosla S (1999) The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13,819-828.
80. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J and Berman N (2000) Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 85,4500-4510.
81. Szulc P, Claustrat B, Marchand F and Delmas PD (2003) Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 88,5240-5247.
82. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML and Iranmanesh A (1992) Attenuation of luteinising hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab 75,707-713.
83. Vermeulen A and Kaufman JM (1995) Ageing of the hypothalamopituitary-testicular axis in men. Horm Res 43,25-28.
84. Vermeulen A and Kaufman JM (2002) Diagnosis of hypogonadism in the aging male. Aging Male 5,170-176.
85. Vermeulen A, Verdonck J and Kaufman JM (1999) Critical evaluation of simple methods for estimation of free testosterone in serum. J Clin Endocrinol Metab 84,3666-3672.
86. von Eckardstein S and Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23,419-425.
87. von Eckardstein A and Wu FCW (2004) Testosterone and cardiovascular diseases. In Nieschlag E and Behre HM (eds), Testosterone. Action, Deficiency, Substitution. 3rd edn. Cambridge University Press, pp 297-331.
88. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE and Swerdloff RS (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 85,964-969.
89. Wang C, Swerdloff R, Kipnes M et al. (2004) New testosterone buccal system (Striant™) delivers physiologic testosterone levels. Pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 89 in press.
90. Webb CM, Adamson DL, de Zeigler D and Collins P (1999a) Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83,437-439.
91. Webb CM, McNeill JG, Hayward CS, de Zeigler D and Collins P (1999b) Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100,1690-1696.
92. Weidner W, Behre H, Beutel M et al. (2001) The Ageing Male. A consensus statement from the joint multidisciplinary working group of the German Society of Andrology, the German Society of Dermatology, the German Society of Endocrinology and the German Society of Urology. Urol Int 66,160-161.
93. WHO (1992) Guidelines for the use of androgens in men. In WHO Special Programme of Research, Development and Research Training in Human Reproduction. Geneva.
94. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M and Sadowski Z (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121, 35-43.
95. Zitzmann M, Rolf C, Brune M, Vieth V and Nieschlag E (2002) Monitoring bone density in hypogonadal men by quantitative phalangeal ultrasound. Bone 31,422-429.
96. Zitzmann M, Depenbusch M, Gromoll J and Nieschlag E (2003) Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88,2049-2054.